SCHEMBL2970698

SCHEMBL2970698

Cc1nc(N2CCc3[nH]c4ccc(N)cc4c3C2)ncc1C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BAZ2B Q9UIF8 10/20 0.54
POLB P06746 2/20 0.40
GAA P10253 2/20 0.40
LMNA P02545 1/20 0.40
PABPC1 P11940 1/20 0.40
ATM Q13315 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 1/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CYP1A1 P04798 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP1B1 Q16678 1/20 0.39
MAPT P10636 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2986272 0.90 SIRT2 (0.46) BAZ2BPOLBGAALMNAPABPC1
SCHEMBL2979164 0.90 BAZ2B (0.54) BAZ2BGAALMNAPABPC1ATM
SCHEMBL2980416 0.85 BAZ2B (0.47) BAZ2BPOLBGAAALDH1A1KDM4E
SCHEMBL2975503 0.85 BAZ2B (0.57) BAZ2BPOLBGAALMNAPABPC1
SCHEMBL2981584 0.84 SIRT2 (0.40) BAZ2BPOLBGAALMNAPABPC1
SCHEMBL2966428 0.84 SIRT2 (0.40) BAZ2BPOLBGAALMNAPABPC1
SCHEMBL2978681 0.83 SIRT2 (0.44) BAZ2BPOLBGAALMNAPABPC1
SCHEMBL2978816 0.83 BAZ2B (0.44) BAZ2BPOLBLMNAPABPC1ATM
SCHEMBL2973482 0.82 SIRT2 (0.44) BAZ2BGAALMNAPABPC1ATM
SCHEMBL2970394 0.82 SIRT2 (0.44) BAZ2BPOLBGAALMNAPABPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772245-B2 Inhibitors of histone deacetylase MIIKANA THERAPEUTICS, INC. (US) 2010-08-10 US disclosed
EP-1851219-A1 FUSED HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF HISTONE DEACETYLASE Miikana Therapeutics, Inc. (US) 2007-11-07 EP disclosed
US-20060199829-A1 Inhibitors of histone deacetylase MIIKANA THERAPEUTICS, INC. 2006-09-07 US disclosed
WO-2006088949-A1 FUSED HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF HISTONE DEACETYLASE MIIKANA THERAPEUTICS, INC. (US) 2006-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199829-A1 Inhibitors of histone deacetylase HDAC1, HDAC2, HDAC11 BAZ2B 33/4885POLB 480/4885GAA 185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.